Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? (Articolo in rivista)

Type
Label
  • Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? (Articolo in rivista) (literal)
Anno
  • 2013-01-01T00:00:00+01:00 (literal)
Alternative label
  • Iole Cucinotto,1 Lucia Fiorillo,1 Simona Gualtieri,1 Mariamena Arbitrio,2 Domenico Ciliberto,1 Nicoletta Staropoli,1 Anna Grimaldi,3 Amalia Luce,3 Pierfrancesco Tassone,1 Michele Caraglia,3 and Pierosandro Tagliaferri1 (2013)
    Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?
    in Journal of Drug Delivery (Online)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Iole Cucinotto,1 Lucia Fiorillo,1 Simona Gualtieri,1 Mariamena Arbitrio,2 Domenico Ciliberto,1 Nicoletta Staropoli,1 Anna Grimaldi,3 Amalia Luce,3 Pierfrancesco Tassone,1 Michele Caraglia,3 and Pierosandro Tagliaferri1 (literal)
Pagina inizio
  • 1 (literal)
Pagina fine
  • 10 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • Volume 2013 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 10 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 905091 (literal)
Note
  • ubMe (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1 Medical Oncology Unit, Department of Experimental and Clinical Medicine, University \"Magna Graecia\" of Catanzaro and \"Tommaso Campanella\" Cancer Center, Campus Salvatore Venuta, Viale Europa, 88100 Catanzaro, Italy 2 Institute of Neurological Science (ISN-CNR), UOS of Pharmacology, Roccelletta di Borgia, 88021 Catanzaro, Italy 3 Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, 80138 Naples, Italy (literal)
Titolo
  • Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? (literal)
Abstract
  • Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms. (literal)
Prodotto di
Autore CNR

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it